Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 14, 2022

SELL
$11.61 - $15.22 $2,438 - $3,196
-210 Reduced 1.78%
11,584 $134,000
Q1 2022

Apr 26, 2022

SELL
$15.39 - $20.25 $18,468 - $24,300
-1,200 Reduced 9.24%
11,794 $228,000
Q4 2021

Jan 21, 2022

SELL
$15.91 - $18.72 $11,932 - $14,040
-750 Reduced 5.46%
12,994 $224,000
Q2 2021

Aug 12, 2021

SELL
$11.45 - $13.96 $13,740 - $16,752
-1,200 Reduced 8.03%
13,744 $184,000
Q1 2021

Apr 23, 2021

SELL
$11.06 - $12.87 $5,530 - $6,435
-500 Reduced 3.24%
14,944 $179,000
Q4 2020

Feb 09, 2021

SELL
$9.33 - $12.48 $3,265 - $4,368
-350 Reduced 2.22%
15,444 $191,000
Q3 2020

Nov 09, 2020

SELL
$10.33 - $14.49 $8,264 - $11,592
-800 Reduced 4.82%
15,794 $165,000
Q2 2020

Jul 09, 2020

SELL
$11.49 - $15.26 $4,596 - $6,104
-400 Reduced 2.35%
16,594 $232,000
Q1 2020

Apr 29, 2020

SELL
$8.11 - $15.23 $51,328 - $96,390
-6,329 Reduced 27.14%
16,994 $200,000
Q4 2019

Jan 13, 2020

SELL
$10.28 - $14.38 $26,933 - $37,675
-2,620 Reduced 10.1%
23,323 $330,000
Q3 2019

Oct 22, 2019

SELL
$10.05 - $14.55 $4,020 - $5,820
-400 Reduced 1.52%
25,943 $273,000
Q2 2019

Aug 01, 2019

SELL
$13.1 - $14.95 $5,240 - $5,980
-400 Reduced 1.5%
26,343 $384,000
Q4 2018

Jan 17, 2019

SELL
$13.96 - $18.26 $11,168 - $14,608
-800 Reduced 2.9%
26,743 $467,000
Q3 2018

Oct 26, 2018

SELL
$13.63 - $15.7 $69,335 - $79,865
-5,087 Reduced 15.59%
27,543 $420,000
Q1 2018

Apr 23, 2018

SELL
$13.8 - $16.99 $1,380 - $1,698
-100 Reduced 0.31%
32,630 $544,000
Q4 2017

Feb 12, 2018

BUY
$11.73 - $14.75 $20,527 - $25,812
1,750 Added 5.65%
32,730 $464,000
Q3 2017

Nov 09, 2017

SELL
$12.06 - $14.12 $38,109 - $44,619
-3,160 Reduced 9.26%
30,980 $437,000
Q2 2017

Aug 11, 2017

BUY
N/A
34,140
34,140 $437,000

Others Institutions Holding INVA

About Innoviva, Inc.


  • Ticker INVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 69,706,000
  • Market Cap $1.33B
  • Description
  • Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...
More about INVA
Track This Portfolio

Track Diligent Investors, LLC Portfolio

Follow Diligent Investors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Diligent Investors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Diligent Investors, LLC with notifications on news.